Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
已完结
20
由 不可二二 发布于 2025/7/18 8:54:11
DOI:10.1182/blood-2022-157691
作者：N. Bartlett,?L. Sehn,?M. Matasar,?S. Schuster,?S. Assouline,?P. Giri,?J. Kuruvilla,?M. Canales,?S. Dietrich,?K. Fay,?M. Ku,?L. Nastoupil,?M. Wei,?S. Yin,?I. To,?Huang Huang,?Juliana Min,?E. Penuel,?L.
文献类型：期刊论文
补充材料：只需要正文
作者：N. Bartlett,?L. Sehn,?M. Matasar,?S. Schuster,?S. Assouline,?P. Giri,?J. Kuruvilla,?M. Canales,?S. Dietrich,?K. Fay,?M. Ku,?L. Nastoupil,?M. Wei,?S. Yin,?I. To,?Huang Huang,?Juliana Min,?E. Penuel,?L.
文献类型：期刊论文
补充材料：只需要正文
American Society of Hematology (ASH)
其它数据库
知网
京公网安备 11010802042870号
